Literature DB >> 22801998

Allopurinol: novel indications in cardiovascular disease.

Allan Struthers, Fiona Shearer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22801998     DOI： 10.1136/heartjnl-2012-302249

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  12 in total

1.  Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry.

Authors:  L Pasina; A L Brucato; C D Djade; P Di Corato; S Ghidoni; M Tettamanti; C Franchi; F Salerno; S Corrao; A Marengoni; M Marcucci; P M Mannucci; A Nobili
Journal:  Eur J Clin Pharmacol       Date:  2014-09-18       Impact factor: 2.953

2.  Xanthine oxidase inhibition alleviates the cardiac complications of insulin resistance: effect on low grade inflammation and the angiotensin system.

Authors:  Hany M El-Bassossy; Malcolm L Watson
Journal:  J Transl Med       Date:  2015-03-06       Impact factor: 5.531

3.  Role of Community Pharmacies for the Detection of Potentially Inappropriate Xanthine Oxidase Inhibitor Prescriptions.

Authors:  L Pasina; S A M Urru; P Minghetti; C Giua
Journal:  Drugs Real World Outcomes       Date:  2015-03

4.  Xanthine oxidase inhibitors in ischaemic heart disease.

Authors:  Mihnea Zdrenghea; Adela Sitar-Tăut; Gabriel Cismaru; Dumitru Zdrenghea; Dana Pop
Journal:  Cardiovasc J Afr       Date:  2016-09-09       Impact factor: 1.167

5.  Effect of allopurinol on blood pressure (author response to Allopurinol on hypertension: insufficient evidence to recommend).

Authors:  Vikram Agarwal; Franz Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-06-25       Impact factor: 3.738

6.  Allopurinol Use during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity.

Authors:  Maria Hoeltzenbein; Katja Stieler; Mary Panse; Evelin Wacker; Christof Schaefer
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

7.  Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis.

Authors:  Jon White; Reecha Sofat; Gibran Hemani; Tina Shah; Jorgen Engmann; Caroline Dale; Sonia Shah; Felix A Kruger; Claudia Giambartolomei; Daniel I Swerdlow; Tom Palmer; Stela McLachlan; Claudia Langenberg; Delilah Zabaneh; Ruth Lovering; Alana Cavadino; Barbara Jefferis; Chris Finan; Andrew Wong; Antoinette Amuzu; Ken Ong; Tom R Gaunt; Helen Warren; Teri-Louise Davies; Fotios Drenos; Jackie Cooper; Shah Ebrahim; Debbie A Lawlor; Philippa J Talmud; Steve E Humphries; Christine Power; Elina Hypponen; Marcus Richards; Rebecca Hardy; Diana Kuh; Nicholas Wareham; Yoav Ben-Shlomo; Ian N Day; Peter Whincup; Richard Morris; Mark W J Strachan; Jacqueline Price; Meena Kumari; Mika Kivimaki; Vincent Plagnol; John C Whittaker; George Davey Smith; Frank Dudbridge; Juan P Casas; Michael V Holmes; Aroon D Hingorani
Journal:  Lancet Diabetes Endocrinol       Date:  2016-01-16       Impact factor: 44.867

Review 8.  Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.

Authors:  Changyi Chen; Jian-Ming Lü; Qizhi Yao
Journal:  Med Sci Monit       Date:  2016-07-17

9.  Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.

Authors:  Jasvinder A Singh; Rekha Ramachandaran; Shaohua Yu; Jeffrey R Curtis
Journal:  BMC Cardiovasc Disord       Date:  2017-03-14       Impact factor: 2.298

10.  A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting.

Authors:  Tejas P Singh; Tristan Skalina; Daniel Nour; Aarya Murali; Sean Morrison; Joseph V Moxon; Jonathan Golledge
Journal:  BMC Cardiovasc Disord       Date:  2018-07-11       Impact factor: 2.298
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.